Topic

All

27
Jul
2021

An Industry that Depends on Diversity Should Defend It

[Editor’s Note: I asked Paul to write in response to a biotech executive who’s marketing a new book that claims diversity and inclusion in business is “the defining scam of our time.”] As CEO of a cell therapy company, I know that the human immune system is a pointillist masterpiece, containing trillions of B and T cells with unique antigen...
Read More
20
Jul
2021

Why We Need mRNA Vaccines in Africa, and For All Who Are Immunocompromised

The HIV pandemic, and COVID-19 pandemic, are intersecting. The relationship between the two conditions is creating an epidemiological synergy that is starting to translate into additional misery for humankind. If we can better understand this phenomenon, we can think more clearly about how to better protect the most vulnerable populations among us – people with HIV, and millions of others...
Read More
19
Jul
2021

From Delta…to Omega?

I hope you are all enjoying your summer break with (finally) being able to see friends and family (and fine food NOT from a delivery service). You are? Great! Now let me spoil some of that for you. This pandemic is not over I understand the inclination to consider the pandemic behind us. In large parts of the US /...
Read More
29
Jun
2021

Immunocompromised People Are Vulnerable to COVID-19. We Owe Them Some Answers

As fully vaccinated citizens in our country and around the globe begin to dip their toes in the waters of a post-vaccination world, there are two groups that deserve greater consideration: immunosuppressed or immunocompromised people. This is not a small group of people. Estimates are that about 6.2 percent of adults ages 18-64 in the US are living with weakened...
Read More
24
Jun
2021

The Other Half: Decentralized Research is The Path to All-Inclusive Medicine 

More than half of the U.S. population is projected to be “other than non-Hispanic white” by 2045. If the current clinical research process doesn’t adapt to these changing population demographics, the life sciences industry will continue developing drugs and devices that are only shown to work for a select few, leaving out the “other half.” Despite efforts, including those from...
Read More
23
Jun
2021

Biopharma’s Racial Justice Work is a Start. But More Needs to Happen

Biopharma leaders have pledged to make their companies more diverse and inclusive. MassBio created an open letter on culture, recruitment, development, sustainability and accountability that has been signed by presidents and CEOs of more than 200 member companies. Large and small companies have described some of their specific efforts in public. Bristol-Myers Squibb aims to double the number of executive...
Read More
1 2 3 52